EcoDrugPlus

Dopamine Receptor D3

Ensembl ID : ENSDLAG00005009728
Gene Symbol: DRD3
2 Cross references
203 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSDLAG00005024600
Gene Symbol: EGLN1
1 Cross references
216 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 3

Ensembl ID : ENSDLAG00005034789
Gene Symbol: EGLN3
1 Cross references
200 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSDLAG00005016556
Gene Symbol: ECE1
1 Cross references
231 Possible Orthologues:

Endothelin Receptor Type Aa

Ensembl ID : ENSDLAG00005018366
Gene Symbol: EDNRAA
1 Cross references
205 Possible Orthologues:

Epidermal Growth Factor Receptor A (Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog, Avian)

Ensembl ID : ENSDLAG00005012486
Gene Symbol: EGFRA
1 Cross references
212 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSDLAG00005007841
Gene Symbol: ERBB2
1 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3b

Ensembl ID : ENSDLAG00005011111
Gene Symbol: ERBB3B
1 Cross references
207 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSDLAG00005006224
Gene Symbol: ERBB4
1 Cross references
222 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4a

Ensembl ID : ENSDLAG00005026285
Gene Symbol: ERBB4A
1 Cross references
243 Possible Orthologues:

Estrogen Receptor 1

Ensembl ID : ENSDLAG00005001062
Gene Symbol: ESR1
1 Cross references
215 Possible Orthologues:

Estrogen Receptor 2b

Ensembl ID : ENSDLAG00005010895
Gene Symbol: ESR2B
1 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).